283 related articles for article (PubMed ID: 31959194)
1. Routes of non-traditional entry into buprenorphine treatment programs.
Champagne-Langabeer T; Swank MW; Langabeer JR
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):6. PubMed ID: 31959194
[TBL] [Abstract][Full Text] [Related]
2. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
[TBL] [Abstract][Full Text] [Related]
3. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
4. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
5. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
6. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
[TBL] [Abstract][Full Text] [Related]
7. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation.
Belden C; Kopak A; Coules C; Friesen T; Hall J; Shukla S
J Subst Use Addict Treat; 2024 Jul; 162():209364. PubMed ID: 38626851
[TBL] [Abstract][Full Text] [Related]
8. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for opioid addiction in community corrections.
Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
[TBL] [Abstract][Full Text] [Related]
10. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
[TBL] [Abstract][Full Text] [Related]
11. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Krawczyk N; Picher CE; Feder KA; Saloner B
Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
[TBL] [Abstract][Full Text] [Related]
12. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
[TBL] [Abstract][Full Text] [Related]
13. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
Speight C; Caiola C; Tyndall DE; Scott ES
J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
15. A call to action: Contingency management to improve post-release treatment engagement among people with opioid use disorder who are incarcerated.
Klemperer EM; Evans EA; Rawson R
Prev Med; 2023 Nov; 176():107647. PubMed ID: 37499918
[TBL] [Abstract][Full Text] [Related]
16. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
17. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
[TBL] [Abstract][Full Text] [Related]
18. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder.
Andraka-Christou B; Nguyen T; Bradford DW; Simon K
J Subst Abuse Treat; 2020 Mar; 110():49-58. PubMed ID: 31952628
[TBL] [Abstract][Full Text] [Related]
20. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]